In early 2020, surgeons at the OHSU Casey Eye Institute performed the first in-body CRISPR gene editing procedure as part of the Phase 1/2 BRILLIANCE clinical trial. Now, new trial results show about 79% of the 14 trial’s participants with a rare form of inherited blindness had measurable improvement after receiving an experimental, CRISPR-based gene editing treatment. (OHSU/Kristyna Wentz-Graff)
